News

12 May 2016

Podcast with Eduardo Bravo – TiGenix – and Samantha Parker – Lysogene – on Adoption of New technologies

Facing the current challenges of coming to market with new ATMPs in Europe, particularly from the standpoint of the barriers to Adoption; this podcast aims to explore in depth several of the topics ar...

Read more
22 Feb 2016

EuropaBio and EBE host a multi-stakeholder debate on the labelling of biosimilar medicines

On 2 February 2016, EuropaBio, the European Association for Bio Industries, and EBE, the European Biopharmaceutical Enterprises, jointly facilitated a multi-stakeholder workshop in Brussels on the labelling of biosimilar medicinal products. 40 people participated in the meeting, including representatives of EU and national associations of patients, physicians and pharmacists. Three representatives from the European Medicines Agency (EMA) attended the meeting as observers. ...

Read more
16 Dec 2015

Event Report: The fourth annual regulatory policy summit organised by the European Biopharmaceutical Enterprises (EBE) and the European Medicines Agency (EMA)

Emerging Medicinal Products – from Laboratory to Patient Use: 14th December 2015, London...

Read more
16 Nov 2015

Interview with Emil Pot, co-founder of ActoGeniX: Europe needs larger investment funds to create a funding escalator from phase II to phase III

With more companies advancing innovative therapies to the end of phase II, the funding requirements of European biotech are spiralling. A new initiative is required to create large and liquid funds to support the next stage of growth and ensure Europe reaps the benefits – both medical and commercial – of its excellent research, says Emil Pot....

Read more
16 Nov 2015

Report from the Alliance for Regenerative Medicine (ARM) Investor Day in London: As cell and gene therapies turn in positive clinical data, attention turns to delivery to patients

After huge investment in the basic science and translation to the clinic, Europe’s advanced therapies companies are accumulating data, which indicate these products have an unprecedented effect. Now effort is needed to develop manufacturing, organise logistics, agree reimbursement and ensure patients get the benefits. Vital Transformation reports for EBE from the ARM Conference....

Read more
08 Sep 2015

Save the date – 14 December 2015: EBE-EMA Regulatory Seminar: Emerging Medicinal Products – from laboratory to patient use

 The fourth annual regulatory policy summit organised by EBE and the European Medicines Agency (EMA) is now open for registration. The 2015 conference will aim at addressing emerging medicinal produ...

Read more
04 Sep 2015

EBE releases White Paper on Personalised Medicine with a focus on key challenges

EBE today launches its White Paper on Personalised Medicine, which explains the concept and benefits of personalised medicine and sets out key challenges to overcome to make personalised medicine...

Read more
21 Apr 2015

Event Report: Launch of European Biopharmaceutical Enterprises (EBE) and Vital Transformation Report, “Europe’s Emerging Science: Putting Advanced Therapies into Practice to Deliver Better Health”

On 15 April, thought leaders met in Lyon, France to take part in a panel discussion and Q&A on the potential of advanced therapies and the challenges we face in implementing them in Europe. The ev...

Read more
27 Mar 2015

WEBINAR: Stem Cells, Gene Therapies, and Tissue Engineering: How do we Put Advanced Therapies into Practice in Europe?

On 16 March, EBE, in collaboration with Vital Transformation and BioVision, held the webinar "Stem Cells, Gene Therapies, and Tissue Engineering: How do we Put Advanced Therapies into Practice in Europe?" in support of the new report on Advanced Therapies being released by EBE and Vital Transformation in Lyon, April 15th at the BioVision conference. The webinar materials and recording are now available for download. ...

Read more
03 Feb 2015

New EBR article by EBE

The January 2015 edition of the European Biopharmaceutical Review (EBR) is now live. Published quarterly, EBR provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world. For our article on the funding challenges of the biopharmaceutical industry please click here. To read the full magazine, please click here....

Read more
1 3 4 5 6 7